Merck KGaA and Abbisko Therapeutics have announced positive results from a late-stage study of pimicotinib in patients with ...

Johnson & Johnson (J&J) has announced that its anti-FcRn antibody nipocalimab has become the first investigational therapy to ...

Novartis and Schrödinger have entered into a research collaboration and licence agreement worth over $2.4bn to advance ...

Novavax has announced that the US Food and Drug Administration (FDA) has lifted its clinical hold on a late-stage study of ...

AstraZeneca (AZ) and Merck – known as MSD outside the US and Canada – have shared positive results from a late-stage study of ...

The companies will aim to discover small molecule treatments aimed at previously undrugged transcription factor targets ...

The companies will use Ascendis’ TransCon technology to develop therapies for metabolic and cardiovascular diseases ...

Daiichi Sankyo has entered into an exclusive licence agreement worth up to $300m with Alteogen to develop a subcutaneous version of its AstraZeneca-partnered antibody-drug conjugate (ADC) Enhertu (fam ...

The National Institute for Health and Care Excellence (NICE) has recommended Blueprint Medicines’ Ayvakyt (avapritinib) to treat patients with the rare blood disorder systemic mastocytosis (SM). The ...

A UK study has demonstrated that interventions to reduce respiratory syncytial virus (RSV) infections could help to reduce antibiotic prescribing and therefore antimicrobial resistance (AMR), which is ...

Johnson & Johnson (J&J) has announced that its pan-FGFR tyrosine kinase inhibitor Balversa (erdafitinib) has been granted marketing authorisation by the Medicines and Healthcare products Regulatory ...